Reviewing Coloplast A/S (OTCMKTS:CLPBY) & Lucid Diagnostics (NASDAQ:LUCD)

Coloplast A/S (OTCMKTS:CLPBY) and Lucid Diagnostics (NASDAQ:LUCD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Earnings & Valuation

This table compares Coloplast A/S and Lucid Diagnostics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coloplast A/S	$3.93 billion	N/A	$734.56 million	$0.30	31.43
Lucid Diagnostics	$4.35 million	24.82	-$45.53 million	($1.34)	-0.74

Coloplast A/S has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Coloplast A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Coloplast A/S and Lucid Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coloplast A/S	16.38%	27.29%	9.40%
Lucid Diagnostics	-1,699.86%	N/A	-124.27%

Institutional & Insider Ownership

74.0% of Lucid Diagnostics shares are held by institutional investors. 6.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Coloplast A/S has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Coloplast A/S and Lucid Diagnostics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coloplast A/S	0	4	0	1	2.40
Lucid Diagnostics	0	0	4	1	3.20

Lucid Diagnostics has a consensus price target of $3.55, indicating a potential upside of 255.78%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than Coloplast A/S.

Summary

Coloplast A/S beats Lucid Diagnostics on 7 of the 13 factors compared between the two stocks.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.